# Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.

> **NCT02970942** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 320 (actual)

## Conditions studied

- Hepatobiliary Disorders
- Non-alcoholic Steatohepatitis

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02970942
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-30
- **Primary completion:** 2020-02-13
- **Final completion:** 2020-03-19
- **Target enrollment:** 320 (ACTUAL)
- **Last updated:** 2021-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02970942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02970942, "Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT02970942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*